TNFRSF17 and plasma cell myeloma: As examples of other mAbs used in the clinic, BIIB059, a mAb directed against anti-blood dendritic cell antigen 2, is being used at 20 mg/kg in Phase II clinical trials [45] and teclistamab, an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma, has been used at approximately 2.5 mg/kg [46].